Are Transplants on the Decline?

Not long ago, the Bone Marrow, then the Peripheral Blood Stem Cell (PBSC) transplant were the key to achieving remissions when more traditional chemotherapy and/or radiation therapy had failed. Transplants are still an important option, the "big wrench" in the doctors toolbox. But using that tool carries risk. Up to 5% of patients die of the procedure due to complications. And there are after-effects like Host vs. Graft Disease which may require treatment.



Fortunately in the last few years, the monoclonal antibody drugs have surfaced as yet another option if remission isn't achieved. The risks are very low compared to transplants. Hopefully even more treatments will come out of research.



It makes me wonder if the number of transplants will decrease as we get more remissions from new treatments. 5% may seem low, but even in my treatment plan I had 2 second opinions to see if rolling those dice was the best option. As all our situations are different, it is always best to ask your medical team, maybe get a second or third opinion on the really big decisions. No good doctor will get upset if you ask for another opinion, as it is common in medical circles and it is your right to do so.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap